Infinity Pharmaceuticals Buy Hold or Sell Recommendation

INFI -- USA Stock  

USD 2.10  0.03  1.41%

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Infinity Pharmaceuticals is 'Sell'. Macroaxis provides Infinity Pharmaceuticals buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding INFI positions. The advice algorithm takes into account all of Infinity Pharmaceuticals available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from INFI buy-and-hold prospective. Please also check Infinity Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool.

Time Horizon

Risk Tolerance

Symbol
Execute Advice
Sell Infinity PharmaceuticalsBuy Infinity Pharmaceuticals
Sell

Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

Inapplicable
For the selected time horizon Infinity Pharmaceuticals has a mean deviation of 2.92, semi deviation of 3.57, standard deviation of 3.75, variance of 14.05, downside variance of 14.6 and semi variance of 12.75
We provide buy, hold, or sell suggestion to complement the regular expert consensus on Infinity Pharmaceuticals. Our dynamic recommendation engine utilizes multi - dimensional algorithm to analyze the organization potential to grow using all technical and fundamental data available at the time. To make sure Infinity Pharmaceuticals is not overpriced, please check out all Infinity Pharmaceuticals fundamentals including its Shares Owned by Institutions, Net Income, Earnings Per Share, as well as the relationship between Price to Sales and Current Ratio . Please also validate Infinity Pharmaceuticals Price to Earning to confirm your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.

Infinity Pharmaceuticals Returns Distribution Density

Mean Return0.35Value At Risk3.63
Potential Upside6.10Standard Deviation3.75
 Return Density 
      Distribution 

Institutional Investors

Security TypeSharesValue
Bvf IncCommon Shares15.2 M29.1 M
Vanguard Group IncCommon Shares2.2 M4.2 M
Wellington Management Group LlpCommon Shares1.6 M3.1 M
Platinum Investment Management LtdCommon Shares1.1 M2.2 M
Blackrock IncCommon Shares972.3 K1.9 M
Dimensional Fund Advisors LpCommon Shares932.4 K1.8 M
Baker Bros Advisors LpCommon Shares580.4 K1.1 M
Susquehanna International Group LlpCall Options124.5 K238 K

Infinity Pharmaceuticals Greeks

α
Alpha over DOW
=0.31
β
Beta against DOW=0.38
σ
Overall volatility
=3.74
Ir
Information ratio =0.07

Infinity Pharmaceuticals Volatility Alert

Infinity Pharmaceuticals shows above average downside volatility of 3.82 for selected time horizon. We advise investors to further inspect Infinity Pharmaceuticals to make sure all market timing and asset allocation strategies are consistent with estimation about Infinity Pharmaceuticals future alpha.
    
 Better Than Average     
    
 Worse Than Average Compare Infinity Pharmaceuticals to competition

Infinity Pharmaceuticals Fundamental Vs Peers

FundamentalsInfinity PharmaceuticalsPeer Average
Return On Equity(59.00) % (15.17) %
Return On Asset(28.60) % (15.64) %
Operating Margin(541.92) % (10.91) %
Current Valuation86.71 M152.14 B
Shares Outstanding56.85 M1.43 B
Shares Owned by Insiders2.87 % 6.91 %
Shares Owned by Institutions49.84 % 18.37 %
Number of Shares Shorted1.22 M3.24 M
Price to Earning1.63 times40.69 times
Price to Book2.62 times14.44 times
Price to Sales19.90 times17.81 times
Revenue6 M9.85 B
Gross Profit(14.83 M)21.75 B
EBITDA(32.07 M)1.41 B
Net Income(30.82 M)517.71 M
Cash and Equivalents49.16 M3.89 B
Cash per Share0.87 times5.17 times
Debt to Equity12.50 % 0.72 %
Current Ratio8.88 times3.30 times
Book Value Per Share0.80 times13.64 times
Cash Flow from Operations(23.91 M)1.25 B
Short Ratio3.71 times2.09 times
Earnings Per Share0.59 times2.30 times
Price to Earnings To Growth0.04 times1.22 times
Number of Employees2210.67 K
Beta3.020.34
Market Capitalization119.39 M29.78 B
Total Asset288.82 M126.86 B
Retained Earnings(595.59 M)38.24 B
Working Capital184.64 M3.58 B
Current Asset254.7 M36.8 B
Current Liabilities70.06 M33.34 B
Z Score-2.8708.73
   Acquisition by Lawrence Bloch of 32200 shares of Infinity Pharmaceuticals subject to Rule 16b-3 [view details]

Infinity Pharmaceuticals Alerts

Trading Alerts and Improvement Suggestions

Infinity Pharmaceuticals appears to be very risky and stock price may revert if volatility continues
Infinity Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported previous year revenue of 6 M. Net Loss for the year was (30.82 M) with loss before overhead, payroll, taxes, and interest of (14.83 M).
INFINITY PHARMACE currently holds about 49.16 M in cash with (23.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.87.
Latest headline from thewellesleysnews.com: Equity Research Analysts Stock Ratings Infinity Pharmaceuticals, Inc. , Madrigal Pharmaceuticals, Inc.

Latest Analysts View

Infinity Pharmaceuticals Current Analysts Recommendations

Target Median Price5.00
Target Mean Price5.00
Recommendation Mean2.30
Target High Price5.00
Number Of Analyst Opinions1
Target Low Price5.00
Please also check Infinity Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool. Please also try Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Search macroaxis.com